| COMPANY |
Caribou Biosciences, Inc. |
| COURT |
United States District Court for the Northern District of California |
| CASE NUMBER |
24-cv-09413 |
| JUDGE |
The Hon. Vince Girdhari Chhabria |
| CLASS PERIOD |
July 14, 2023, through July 16, 2024 |
| SECURITY TYPE |
Securities |
LEAD PLAINTIFF DEADLINE IS FEBRUARY 24, 2025.
If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at info@ktmc.com.
Case Background:
Caribou is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies. Caribou’s pipeline includes allogeneic, or “off-the-shelf,” cell therapies from its chimeric antigen receptor-T (“CAR-T”) cell and CAR-natural killer (“CAR-NK”) cell platforms. Allogeneic cell therapies are referred to as “off-the-shelf” because they use cells that have already been collected from a donor, and which were modified, multiplied, and stored in a facility, before being infused into a patient. In contrast, autologous CAR-T cell therapies use a patient’s own immune cells. Caribou’s lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that the company is evaluating in patients with, inter alia, relapsed or refractory large B cell non-Hodgkin lymphoma (“r/r B-NHL”) in the company’s ongoing ANTLER Phase 1 clinical trial, with a focus on second-line large B cell lymphoma (“LBCL”).
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) they had overstated CB-010’s safety, efficacy, and durability relative to approved autologous CAR-T cell therapies in treating patients with r/r B-NHL and/or LBCL, as well as CB-010’s overall clinical results and commercial prospects; (2) Caribou was at significant risk of having insufficient cash, liquidity, and/or other capital to fund its current business operations, including preclinical research activities associated with the allogeneic CAR-NK platform; (3) the foregoing was likely to have a significant negative impact on Caribou’s business and operations; and (4) as a result, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
What is a Lead Plaintiff?
A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.